Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 6, 2026Circulation

Abstract MPTH69: Metabolic Dysfunction-Associated Steatotic Liver Disease Across the Cardiovascular-Kidney-Metabolic Spectrum: Insights from the CARDIA Study

View Full Paper
Ask AI
Bookmark
Share

Authors

JOJohn OstrominskiBSBaiyang SunEWErin Wong

Discussion

Loading...

Member takes

Overview

Prospective study shows metabolic dysfunction-associated steatotic liver disease increases long-term adverse outcomes and cardiovascular events.

Key Points

  • To evaluate the prevalence and impact of metabolic dysfunction-associated steatotic liver disease across the cardiovascular-kidney-metabolic spectrum.
  • Conducted a prospective study using the CARDIA cohort.
  • Performed abdominal computed tomography on participants.
  • Defined MASLD by hepatic steatosis and cardiometabolic criteria.
  • Conducted subgroup analyses based on CKM stage.
  • 24% of participants had MASLD, increasing prevalence with higher CKM stages.
  • MASLD associated with a higher incidence of all-cause death and cardiovascular events.
  • After adjustments, MASLD correlated with significant long-term adverse outcomes.

Cite This Study

Ostrominski et al. (2026) studied this question.

synapsesocial.com/papers/69faa30204f884e66b533a75https://doi.org/10.1161/cir.153.suppl_1.mpth69
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Relationship between metabolic dysfunction-associated steatotic liver disease and cardiovascular mortality risk in individuals with CKM stages 0-2: Mediating roles of inflammation and insulin resistance.2026
  2. 2Stratified Burden of MASLD in Cardiovascular-Kidney-Metabolic syndrome: Stage-Dependent Prevalence and Insulin Resistance-Driven Cardiovascular Mortality2025
  3. 3Population‐Based Study on the Coexistence of Metabolic Dysfunction‐Associated Steatotic Liver Disease and Chronic Kidney Disease2025 · 20 citations
  4. 4Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease2024 · 21 citations
  5. 5Metabolic dysfunction-associated steatotic liver disease (MASLD) can be a possible predictive factor of incident CKD: NAGALA cohort study2025 · 4 citations